Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.
OBJECTIVE
Our previous study demonstrated an siRNA-mediated, allele-specific silencing of mutant genes that cause amyotrophic lateral sclerosis. To improve siRNA design for better therapeutic use of RNA interference, we systematically tested the base-pairing mismatch strategy in the design of asymmetric siRNA.


METHODS
A naturally symmetric siRNA that targets the human Cu Zn superoxide dismutase G85R mutant allele was modified by placing either 1 or 2 mismatches at the end of the siRNA from position 1 to 4 at each time. The target preference and silencing efficacy of modified siRNA were measured using a modified dual luciferase system.


RESULTS
The modification of single base-pairing mismatch successfully achieved the conversion of the siRNA that was originally favored to the antisense of the mutant allele to the one that was favored to the sense strand of the gene. Compared to the single-mismatched siRNA, those with double-mismatch at one end demonstrated an increased asymmetry, and thus, an enhanced specificity and efficacy of gene silencing. In addition, the siRNA with double-mismatch at both ends remained in symmetry.


CONCLUSIONS
Our results suggest the effectiveness of converting a symmetric siRNA to an asymmetric one by introducing mismatches into its structure, and the superiority of double-mismatched siRNA to single-mismatched siRNA in producing selective gene silencing resulting from the disruption of siRNA symmetry. The double-mismatch strategy is an improvement of the single-mismatch method and could be useful in the design of effective siRNAs for the treatment of diseases caused by dominant, gain-of-function gene mutations, such as ALS.
Geng
Chang-ming
CM
Department of Neurology, Shanghai PLA 85 Hospital, Shanghai 200052, China.
Ding
Hong-liu
HL
D000483:Alleles; D000690:Amyotrophic Lateral Sclerosis / Q000235:genetics*; D020137:Base Pair Mismatch / Q000187:drug effects / Q000235:genetics*; D002460:Cell Line; D020868:Gene Silencing / Q000187:drug effects*; D006801:Humans; D009154:Mutation / Q000502:physiology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D034741:RNA, Small Interfering / Q000494:pharmacology*; D013482:Superoxide Dismutase / Q000235:genetics; D000072105:Superoxide Dismutase-1
D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering; C000606290:SOD1 protein, human; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1